Clinical Trials Browser

Phase 1/2 × siltuximab × Plasma cell × Clear all

NCT01531998 2015-06-19

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Phase 1/2 Completed

14 enrolled 6 charts

Multiple Myeloma, Neoplasms, Plasma Cell